Bright Minds Biosciences Announces Resignation of Board Member Post published:January 12, 2023 Post category:Press Release
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement Post published:December 2, 2022 Post category:Press Release
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors Post published:September 8, 2022 Post category:Press Release
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Comments on Recent Trading Activity Post published:August 18, 2022 Post category:Press Release
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization Post published:June 27, 2022 Post category:Press Release
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome Post published:May 22, 2022 Post category:Press Release
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties Post published:May 2, 2022 Post category:Press Release
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Post published:March 14, 2022 Post category:Press Release